These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 8427961)

  • 1. Increased thrombin generation in a child with a combined factor IX and protein C deficiency.
    Negrier C; Berruyer M; Durin A; Philippe N; Dechavanne M
    Blood; 1993 Feb; 81(3):690-5. PubMed ID: 8427961
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thrombin generation is not increased in the blood of hemophilia B patients after the infusion of a purified factor IX concentrate.
    Mannucci PM; Bauer KA; Gringeri A; Barzegar S; Bottasso B; Simoni L; Rosenberg RD
    Blood; 1990 Dec; 76(12):2540-5. PubMed ID: 2265248
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined factor IX and protein C deficiency in a child: thrombogenic effects of two factor IX concentrates.
    Negrier C; Vial J; Vinciguerra C; Berruyer M; Dechavanne M
    Am J Hematol; 1995 Feb; 48(2):120-4. PubMed ID: 7847325
    [TBL] [Abstract][Full Text] [Related]  

  • 4. No activation of the common pathway of the coagulation cascade after a highly purified factor IX concentrate.
    Mannucci PM; Bauer KA; Gringeri A; Barzegar S; Santagostino E; Tradati FC; Rosenberg RD
    Br J Haematol; 1991 Dec; 79(4):606-11. PubMed ID: 1772782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduced coagulation activation following infusion of a highly purified factor IX concentrate compared to a prothrombin complex concentrate.
    Hampton KK; Preston FE; Lowe GD; Walker ID; Sampson B
    Br J Haematol; 1993 Jun; 84(2):279-84. PubMed ID: 8398831
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A cross-over pharmacokinetic study of a double viral inactivated factor IX concentrate (15 nm filtration and SD) compared to a SD factor IX concentrate.
    Goudemand J; Peynet J; Chambost H; Négrier C; Briquel ME; Claeyssens S; Derlon-Borel A; Guérois C; Caron C; Scherrmann JM; Debray M; Bridey F
    Thromb Haemost; 1998 Dec; 80(6):919-24. PubMed ID: 9869161
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A cross-over pharmacokinetic and thrombogenicity study of a prothrombin complex concentrate and a purified factor IX concentrate.
    Thomas DP; Hampton KK; Dasani H; Lee CA; Giangrande PL; Harman C; Lee ML; Preston FE
    Br J Haematol; 1994 Aug; 87(4):782-8. PubMed ID: 7986719
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Purified factor IX using monoclonal immunoaffinity technique: clinical trials in hemophilia B and comparison to prothrombin complex concentrates.
    Kim HC; McMillan CW; White GC; Bergman GE; Horton MW; Saidi P
    Blood; 1992 Feb; 79(3):568-75. PubMed ID: 1531035
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hereditary factor VII and IX deficiencies in a large kindred.
    Hall CA; London AR; Moynihan AC; Dodds WJ
    Br J Haematol; 1975 Feb; 29(2):319-28. PubMed ID: 1191552
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monitoring once-weekly recombinant factor IX prophylaxis in hemophilia B with thrombin generation assay and factor IX activity.
    Nummi V; Jouppila A; Lassila R
    Int J Lab Hematol; 2017 Aug; 39(4):359-368. PubMed ID: 28406575
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biochemical and in vivo properties of high purity factor IX concentrates.
    Berntorp E; Björkman S; Carlsson M; Lethagen S; Nilsson IM
    Thromb Haemost; 1993 Nov; 70(5):768-73. PubMed ID: 8128433
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics, thrombogenicity and safety of a double viral inactivated factor IX concentrate compared with a prothrombin complex concentrate.
    Ruiz-Sáez A; Hong A; Arguello A; Echenagucia M; Boadas A; Fabbrizzi F; Minichilli F; Bosch NB
    Haemophilia; 2005 Nov; 11(6):583-8. PubMed ID: 16236107
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mathematical model of thrombin generation and bleeding phenotype in Amish carriers of Factor IX:C deficiency vs. controls.
    Gupta S; Bravo MC; Heiman M; Nakar C; Brummel-Ziedins K; Miller CH; Shapiro A
    Thromb Res; 2019 Oct; 182():43-50. PubMed ID: 31446339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of coagulation equilibrium at baseline and during factor VIII and factor IX replacement in haemophiliacs.
    Négrier C; Menart C; Attali O; Petit PY; Lienhart A; Dechavanne M; Ingerslev J
    Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S135-41. PubMed ID: 9819045
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hemostatic enzyme generation in the blood of patients with hereditary protein C deficiency.
    Bauer KA; Broekmans AW; Bertina RM; Conard J; Horellou MH; Samama MM; Rosenberg RD
    Blood; 1988 May; 71(5):1418-26. PubMed ID: 2965928
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Presence of inactive factor ix in variants of hemophilia, type B, and in carriers of hemophilia B].
    Elodi S
    Minerva Med; 1975 Jun; 66(42):2037-43. PubMed ID: 1138213
    [No Abstract]   [Full Text] [Related]  

  • 17. Markers of hypercoagulability in patients with hemophilia B given repeated, large doses of factor IX concentrates during and after surgery.
    Santagostino E; Mannucci PM; Gringeri A; Tagariello G; Baudo F; Bauer KA; Rosenberg RD
    Thromb Haemost; 1994 Jun; 71(6):737-40. PubMed ID: 7974341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Coagulation-dependent inhibition of fibrinolysis: role of carboxypeptidase-U and the premature lysis of clots from hemophilic plasma.
    Broze GJ; Higuchi DA
    Blood; 1996 Nov; 88(10):3815-23. PubMed ID: 8916945
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High purity factor IX and prothrombin complex concentrate (PCC): pharmacokinetics and evidence that factor IXa is the thrombogenic trigger in PCC.
    Philippou H; Adami A; Lane DA; MacGregor IR; Tuddenham EG; Lowe GD; Rumley A; Ludlam CA
    Thromb Haemost; 1996 Jul; 76(1):23-8. PubMed ID: 8819246
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of prothrombin activating snake venoms to measure human prethrombin 2: absence of prethrombin 2 in serum.
    Aronson DL; Franza BR; Bagley J
    Thromb Res; 1984 Jun; 34(5):419-29. PubMed ID: 6377573
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.